drugset / Trial / NCT03549000
A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study was to assess the safety, tolerability, and preliminary anti-tumor activity of experimental medication NZV930 alone and when combined with PDR001 and/or NIR178, in patients with advanced cancers
Timeline
- Start
- 2018-07-18
- Primary completion
- 2022-10-17
- Completion
- 2022-10-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NIR178 | Unknown | — | Oral |